Metabolic & Weight Peptides

A to Z Index · Healing & Repair Peptides · Growth Hormone Secretagogues · Bioregulator Peptides · Cosmetic & Skin Peptides · Metabolic & Weight Peptides · Human Trials

• 5-Amino-1MQLibrary entryA cell-permeable small molecule (not a peptide) that blocks the enzyme NNMT.Conditions: Fat loss, obesity & body recomposition, Dementia, Alzheimer's & cognitive decline, Multiple sclerosis
• AdipotideLibrary entryAn experimental compound designed to target the blood vessels that support white fat tissue; animal kidney findings are central to its story.
• AICARLibrary entryA research compound that activates AMPK, nicknamed the “exercise pill”; prohibited in sport and not approved for human use.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Concussion, traumatic brain injury & stroke recovery, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes
• AmycretinLibrary entryA single molecule that activates both GLP-1 and amylin receptors, tested by injection and as a tablet in early obesity trials.Conditions: Fat loss, obesity & body recomposition, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes, Osteoarthritis, cartilage loss & avoiding joint replacement
• Amylin (Islet Amyloid Polypeptide)Library entryA 37-amino-acid hormone released with insulin that slows stomach emptying and signals fullness; pramlintide (Symlin) is a synthetic version.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Fat loss, obesity & body recomposition
• Anamorelin (non-peptide)Library entryAn oral ghrelin-receptor agonist approved in Japan (Adlumiz) for cancer cachexia; it raises GH and IGF-1 and increases appetite and lean mass.Conditions: Fat loss, obesity & body recomposition, Fatigue & low energy (incl. midlife), Muscle gain, sarcopenia & building muscle after 40, Osteoporosis and bone density
• AOD-9604Library entryA modified fragment of growth hormone that acts through a different pathway than GH.Conditions: Osteoarthritis, cartilage loss & avoiding joint replacement
• BimagrumabLibrary entryA monoclonal antibody that blocks activin type II receptors, studied by Lilly (via Versanis) to cut fat while keeping muscle during GLP-1 weight loss.Conditions: Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, Lung health, asthma & COPD, Muscle gain, sarcopenia & building muscle after 40
• CagrilintideLibrary entryAn investigational long-acting amylin analog; CagriSema combines it with semaglutide.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney)
• CagriSema (Cagrilintide + Semaglutide)Library entryA once-weekly fixed combination of cagrilintide (amylin analog) and semaglutide (GLP-1) tested in the phase 3 REDEFINE program.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Insulin resistance, prediabetes & type 2 diabetes
• Cardarine (GW501516, non-peptide)Library entryA PPAR-δ agonist paired with retatrutide in fat-loss discussion.Conditions: Fat loss, obesity & body recomposition, Menopause & perimenopause, Fatty liver & elevated liver enzymes, Insulin resistance, prediabetes & type 2 diabetes
• CotadutideLibrary entryA GLP-1/glucagon dual agonist from AstraZeneca studied in diabetes, fatty liver and kidney disease; development stopped in 2023.Conditions: Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney)
• DapiglutideLibrary entryA once-weekly dual GLP-1 and GLP-2 receptor agonist from Zealand Pharma, studied in short bowel models and in obesity.Conditions: Chronic and systemic inflammation, Fat loss, obesity & body recomposition
• DulaglutideLibrary entryA once-weekly GLP-1 receptor agonist (two GLP-1 analog chains joined to an antibody Fc fragment), sold as Trulicity.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Cognition, focus & brain performance, Concussion, traumatic brain injury & stroke recovery
• EcnoglutideLibrary entryA once-weekly cAMP-biased GLP-1 receptor agonist from Sciwind Biosciences, approved in China in 2026 for type 2 diabetes and weight management.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, Osteoarthritis, cartilage loss & avoiding joint replacement
• EloralintideLibrary entryAn investigational selective amylin-receptor agonist studied in once-weekly phase 2 obesity trials.Conditions: Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Osteoarthritis, cartilage loss & avoiding joint replacement
• ExenatideLibrary entryA 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Cognition, focus & brain performance, Concussion, traumatic brain injury & stroke recovery
• GHRP-2Library entryA synthetic growth hormone secretagogue that activates the ghrelin receptor and can increase appetite.Conditions: Fat loss, obesity & body recomposition
• GHRP-6Library entryAn early synthetic hexapeptide ghrelin-receptor agonist that releases growth hormone and strongly increases appetite.Conditions: Anti-aging & longevity, Concussion, traumatic brain injury & stroke recovery, Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes
• GIP (Gastric Inhibitory Polypeptide)Library entryA 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.Conditions: Anxiety and panic, Skin sensitivity and body aches on GLP-1 medicines, Celiac disease and gluten sensitivity, Chronic and systemic inflammation
• GlucagonLibrary entryA 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.Conditions: Anxiety and panic, Delayed gastric emptying on GLP-1 medicines, Fatty liver & elevated liver enzymes, Gallbladder and gallstones
• HGH Fragment 176-191Library entryThe C-terminal 16 amino acids of human growth hormone, studied in animals for fat metabolism; AOD-9604 is a modified version.
• L-CarnitineLibrary entryAn amino acid derivative that carries fatty acids into mitochondria for energy production.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Dementia, Alzheimer's & cognitive decline, Heart repair: after heart attack, heart failure & enlarged heart, High cholesterol and statins
• Lipo-B Injections (non-peptide)Library entryLipotropic injections (methionine, inositol, choline) with vitamin B12 added, sold by med spas and telehealth clinics; not peptides.
• Lipo-C / MIC Injections (non-peptide)Library entryMethionine, inositol and choline (often with B12 or L-carnitine) sold as "lipotropic" injections; not peptides.
• LiraglutideLibrary entryA once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Cognition, focus & brain performance, Concussion, traumatic brain injury & stroke recovery
• LixisenatideLibrary entryA 44-amino-acid once-daily GLP-1 receptor agonist based on exendin-4; sold as Adlyxin/Lyxumia and in Soliqua with insulin glargine.Conditions: Delayed gastric emptying on GLP-1 medicines, Fat loss, obesity & body recomposition, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes
• MariTide (Maridebart Cafraglutide)Library entryAmgen's once-monthly antibody-peptide conjugate that blocks GIP receptors and activates GLP-1 receptors, in phase 3 obesity trials. News and evidence page only.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Fat loss, obesity & body recomposition, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes
• MazdutideLibrary entryA dual GLP-1 and glucagon receptor agonist with approvals announced in China for weight management and type 2 diabetes.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Dementia, Alzheimer's & cognitive decline, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes
• MOTS-cLibrary entryA 16-amino-acid peptide encoded in mitochondrial DNA.Conditions: Insulin resistance, prediabetes & type 2 diabetes, Fat loss, obesity & body recomposition, Fatigue & low energy (incl. midlife), Fatty liver & elevated liver enzymes
• Orforglipron (Foundayo, non-peptide)Library entryAn oral small-molecule GLP-1 receptor agonist (not a peptide); FDA-approved as Foundayo on April 1, 2026 for chronic weight management.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Concussion, traumatic brain injury & stroke recovery, Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes
• OxyntomodulinLibrary entryA natural 37-amino-acid gut hormone that activates both GLP-1 and glucagon receptors; the model for the newer GLP-1/glucagon dual agonists.Conditions: Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, PCOS, Post-surgical inflammation and surgery recovery
• PancragenLibrary entryA four-amino-acid peptide (Lys-Glu-Asp-Trp) studied for pancreatic function and age-related changes in glucose metabolism.
• PemvidutideLibrary entryAn investigational once-weekly GLP-1/glucagon dual agonist studied for obesity and fatty liver disease (MASH).Conditions: Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes
• PetrelintideLibrary entryA long-acting human amylin analog from Zealand Pharma, in phase 2 obesity trials.Conditions: Atherosclerosis, cardiovascular disease & high blood pressure, Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney)
• RetatrutideLibrary entryA single-molecule triple agonist (GLP-1, GIP and glucagon receptors).Conditions: Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, Fatty liver & elevated liver enzymes, Dementia, Alzheimer's & cognitive decline
• SemaglutideLibrary entryThe active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).Conditions: Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Anti-aging & longevity
• SetmelanotideLibrary entryAn FDA-approved melanocortin-4 receptor agonist for rare genetic obesity (POMC, PCSK1, LEPR deficiency and Bardet-Biedl syndrome).Conditions: Fat loss, obesity & body recomposition, High cholesterol and statins, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney)
• SLU-PP-332Library entryAn estrogen-related-receptor (ERR) agonist (non-peptide) described as an "exercise mimetic." It copies endurance training at the gene level.Conditions: Fat loss, obesity & body recomposition
• SurvodutideLibrary entryAn investigational long-acting GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.Conditions: Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney)
• TesamorelinLibrary entryGH pulse → liver IGF-1 → mTOR and PI3K-AKT (muscle).Conditions: Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, Muscle gain, sarcopenia & building muscle after 40, Dementia, Alzheimer's & cognitive decline
• Tesofensine (non-peptide)Library entryAn oral triple reuptake inhibitor (serotonin, norepinephrine, dopamine).Conditions: Fat loss, obesity & body recomposition, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Dementia, Alzheimer's & cognitive decline, Insulin resistance, prediabetes & type 2 diabetes
• TirzepatideLibrary entryA prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.Conditions: Delayed gastric emptying on GLP-1 medicines, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Menopause & perimenopause, Anti-aging & longevity
• VK2735Library entryA GIP/GLP-1 dual agonist from Viking Therapeutics, tested as a weekly injection and an oral tablet.Conditions: Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes

Research and education only. Not medical advice. Summaries and source links only, no dosing advice.